Eli Lilly and Novo Nordisk already produce popular GLP-1s in the Triangle. A Swiss drugmaker says its future Wake County site ...

Eli Lilly’s (NYSE:LLY) stock is still recovering after the drugmaker released trial data earlier this month on its closely watched obesity pill that underwhelmed Wall Street. In a key late-stage trial ...

As GLP-1 adoption grows and new applications for the drugs come to light, experts say that could have sweeping impacts for ...

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Burke Wealth Management, an investment management company, released its “Focused Growth Strategy” second-quarter 2025 ...

The Trump administration’s sweeping tariffs have sent ripples through the healthcare sector in 2025. Last week, the US ...